Metis Global Partners LLC Has $318,000 Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Metis Global Partners LLC boosted its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 4.4% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 1,720 shares of the medical research company’s stock after acquiring an additional 72 shares during the quarter. Metis Global Partners LLC’s holdings in Charles River Laboratories International were worth $318,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Principal Financial Group Inc. boosted its holdings in Charles River Laboratories International by 3.6% in the 3rd quarter. Principal Financial Group Inc. now owns 60,501 shares of the medical research company’s stock valued at $11,917,000 after purchasing an additional 2,126 shares during the period. Assetmark Inc. boosted its holdings in Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 173 shares during the period. Covestor Ltd boosted its holdings in Charles River Laboratories International by 40.9% in the 3rd quarter. Covestor Ltd now owns 327 shares of the medical research company’s stock valued at $65,000 after purchasing an additional 95 shares during the period. Venturi Wealth Management LLC boosted its holdings in Charles River Laboratories International by 61.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 1,616 shares of the medical research company’s stock valued at $318,000 after purchasing an additional 614 shares during the period. Finally, WCM Investment Management LLC boosted its holdings in Charles River Laboratories International by 33.3% in the 3rd quarter. WCM Investment Management LLC now owns 10,367 shares of the medical research company’s stock valued at $2,056,000 after purchasing an additional 2,589 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, CEO James C. Foster purchased 6,075 shares of the stock in a transaction dated Thursday, February 20th. The stock was bought at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the transaction, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. This represents a 3.42 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Birgit Girshick purchased 1,514 shares of the stock in a transaction dated Thursday, February 20th. The shares were acquired at an average price of $164.63 per share, with a total value of $249,249.82. Following the transaction, the chief operating officer now owns 55,058 shares in the company, valued at $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Trading Up 1.2 %

CRL opened at $169.55 on Friday. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $8.67 billion, a PE ratio of 1,130.31, a PEG ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 1-year low of $150.79 and a 1-year high of $275.00. The firm has a 50-day moving average price of $169.69 and a two-hundred day moving average price of $186.19.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same quarter last year, the company posted $2.46 EPS. As a group, equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

CRL has been the subject of a number of analyst reports. Evercore ISI raised their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. Morgan Stanley reduced their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a report on Wednesday, February 5th. Citigroup raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and raised their price objective for the stock from $155.00 to $175.00 in a report on Tuesday. CLSA downgraded shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective for the company. in a report on Monday, November 18th. Finally, Redburn Atlantic raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price objective for the company in a report on Monday. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, Charles River Laboratories International currently has an average rating of “Hold” and an average price target of $198.36.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).